News
Article
AstraZeneca Announces Plans to Harmonize Global Listing Structure for Stock Exchanges Alongside Positive Enhertu Updates
Author(s):
Key Takeaways
- AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK.
- Enhertu shows superior outcomes in early-stage HER2-positive breast cancer, outperforming T-DM1 in the DESTINY-Breast05 trial.
The move will allow stocks to be traded across the US, London, and Stockholm exchanges.
AstraZeneca shares will be harmonized across New York, London, and Stockholm.
Stock.adobe.com
AstraZeneca announced plans to harmonize its share listing structure across its global presence.1 The company issued a statement announcing the plans and recommended a harmonized listing structure across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange.
Why is AstraZeneca harmonizing its shares?
In a press release, AstraZeneca chair Michel Demare said, “Today we set out our proposed harmonized listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future.”
The move will require AstraZeneca to upgrade its existing US shares and replacing them with direct shares. This will allow the shares to be traded across the three major global listing exchanges.
The announcement comes as AstraZeneca is sharing positive news about one of its lead assets, Enhertu. According to a recent statement, the drug demonstrated statistically significant and clinically meaningful improvement in a recent clinical trial.2
AstraZeneca’s executive vice president of oncology and haematology R&D Susan Galbraith said, “This landmark trial is the first to directly compare Enhertu and T-DM1 in early breast cancer, and the results clearly show that Enhertu delivers superior outcomes, indicating that it may be a better option for patients with high-risk HER2-positive disease in the post-neoadjuvant setting. These results from DESTINY-Breast05, coupled with DESTINY-Breast11, underscore our commitment to moving Enhertu into early-stage HER2-positive breast cancer where patients can achieve sustained long-term outcomes, increasing the opportunity for cure.”
In the same press release, Daiichi Sankyo global head of R&D Ken Takeshita added, “In patients with early breast cancer with residual disease following neoadjuvant treatment, it is critical to optimise treatment as this represents the last opportunity to prevent progression to metastatic disease. The results of DESTINY-Breast05 demonstrate that treatment with Enhertu following surgery increases the length of time patients are able to live free of invasive disease compared to the existing standard of care, potentially offering patients with HER2-positive early breast cancer a new treatment approach in this curative-intent setting."
FDA also recently granted Enhertu (plus pertuzamab) priority review as a 1st-line treatment for HER2-positive metastatic breast cancer.3
In a statement issued earlier this month, Galbraith said, “The DESTINY-Breast09 trial showed that treating patients with HER2-positive metastatic breast cancer with Enhertu in combination with pertuzumab until progression in the first-line setting produced a new landmark of more than 40 months for progression-free survival and nearly doubled the number of patients with no evidence of disease on imaging. This marks the first major evolution in treatment in this first-line setting in more than a decade – a setting where a strong response is crucial, as up to one third of patients may not receive second-line therapy.”
In the same press release, Takeshita added, “Enhertu in combination with pertuzumab delayed disease progression for more than three years compared to around two years with current standard of care as a first-line treatment for patients with HER2-positive metastatic breast cancer. Receiving Priority Review moves us closer to offering Enhertu to patients even earlier in the metastatic treatment pathway as a potential new first-line treatment option.”
Sources
- AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange. AstraZeneca. September 29, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html
- Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial in patients with high-risk early breast cancer following neoadjuvant therapy. AstraZeneca. September 29, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-idfs-in-early-bc-in-db-05.html
- Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer. AstraZeneca. September 24, 2025. Accessed September 29, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-granted-priority-review-us-1st-line-treatment-patients-with-her2-positive-metastatic-breast-cancer.html
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
